A practical reference on storage stability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-03. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Twenty isotopes and six nuclear isomers (excited states of an isotope) of berkelium have been characterized, with mass numbers ranging from 233 to 253 (except 237). All of them are radioactive. The longest half-lives are observed for 247Bk (1,380 years), 248Bk (unknown, almost surely over 300 years), and 249Bk (327.2 days); other isotopes are less than a week. The isotope which is the easiest to synthesize (reactor neutron capture) is berkelium-249. This emits mostly soft β-particles which are inconvenient for detection. Its alpha radiation is rather weak (1.45×10−3%) with respect to the β-radiation, but is sometimes used to detect this isotope. The second important berkelium isotope, berkelium-247, is beta-stable and an alpha emitter, as are most long-lived actinide isotopes.
=== SMNI suspension and ICC investigation === Despite sustained domestic popularity, Duterte found himself increasingly politically isolated. SMNI, which hosted his talk show Gikan sa Masa, Para sa Masa, was later suspended (first for 30 days, and later indefinitely) by the National Telecommunications Commission on grounds of alleged dissemination of fake information. Gikan was also suspended after ACT Teachers Representative France Castro filed a complaint against Duterte for allegedly threatening her life during one of the shows. Duterte initially intended to speak to Marcos about the SMNI suspension issue as it has affected his talk show, decrying the suspension as censorship. Additionally, the Liberal Party, who opposed Marcos' 2022 presidential campaign, were increasingly silent in criticizing the Marcos administration, instead, directing criticism at Duterte and his daughter, Vice President Sara. Duterte and his former aide, Senator Bong Go, also faced alleged plunder charges initiated in July 2024 by Duterte's staunch critic, former Senator Antonio Trillanes. Political analysis noted that the Marcos administration subtly shifted its approach toward controversies involving Duterte. Despite Marcos' early assurance of the Philippines' non-cooperation on the looming International Criminal Court (ICC) investigation on Duterte's war on drugs, conflicting statements and moves by House Speaker Romualdez, the House, Marcos' Justice Secretary Crispin Remulla and Solicitor General Menardo Guevarra muddled the administration's official stance.
=== Use of libel law to suppress criticism === Hari used threats of suing for libel to prevent critics revealing his misrepresentations. After British bloggers criticised his critique of Nick Cohen's What's Left: How Liberals Lost Their Way for factual and interpretive errors, Hari used libel law against a blogger who wrote that "a reputation for making things up should spell career death", leading to the blogger removing the post.
2(Ag(NH3)2)+ + RCHO + 2OH− → RCOOH + 2Ag + 4NH3. The size and shape of the nanoparticles produced are difficult to control and often have wide distributions. However, this method is often used to apply thin coatings of silver particles onto surfaces and further study into producing more uniformly sized nanoparticles is being done.
The Spanish navy had been totally dismantled by a disastrous naval policy and relegated to the background by the urgency of the war against Napoleon itself. To 1817, Tsar Alexander supported reactionary governments. Ferdinand VII applied to the Tsar to purchase vessels. The Tsar agreed to this request with the offer of the sale of some of his own vessels. The agreement was finally negotiated at Madrid, between Dmitry Tatishchev, Russian ambassador, and Eguia, Minister of war. It was apparently known only to these two, and to the king himself. The text of the treaty of sale has not been found in the Spanish naval archives. This diplomatic transaction was veiled in the deepest secrecy against Spanish Navy and Minister of Navy. The requested fleet would consist of 5 warships and 3 frigates. The squadron would be delivered to Cadiz, duly armed, and supplied. The arrival of the Russian fleet in Cadiz in February 1818 was not to the liking of the Spanish navy, which was dissatisfied with the state of deterioration in which some supposedly new ships were found: between 1820 and 1823 all the warships were scrapped as being useless. This fiasco put an end to the whole plan to reconquer the Rio de la Plata, which would end with the uprising of the Spanish Army in Cadiz (Trienio Liberal). In 1818 one of the frigates (Maria Isabel aka Patrikki) was captured in the Pacific, after the uprising of one of the Spanish troop transports that went over to the side of the American rebels delivering all the keys, routes and signals for the capture of the frigate.
Sources: en.wikipedia.org
==== Supplementation ==== Numerous pharmaceutical preparations of magnesium and dietary supplements are available. Most people get enough magnesium through a healthy diet, though supplements may help in specific conditions like magnesium deficiency, pregnancy complications, or certain chronic health issues. A 2014 literature review found limited evidence supporting oral magnesium supplementation for migraine prevention, suggesting that increasing dietary magnesium intake may be a more effective option for patients open to lifestyle changes.
=== Peptide transport === TAP-mediated peptide transport is a multistep process. The peptide-binding pocket is formed by TAP-1 and TAP-2. Association with TAP is an ATP-independent event, 'in a fast bimolecular association step, peptide binds to TAP, followed by a slow isomerisation of the TAP complex'. It is suggested that the conformational change in structure triggers ATP hydrolysis and so initiates peptide transport. Both nucleotide-binding domains (NBDs) are required for peptide translocation, as each NBD cannot hydrolyse ATP alone. The exact mechanism of transport is not known; however, findings indicate that ATP binding to TAP-1 is the initial step in the transport process, and that ATP bound to TAP-1 induces ATP binding in TAP-2. It has also been shown that undocking of the loaded MHC class I is linked to the transport cycle of TAP caused by signals from the TAP-1 subunit.
Lubiprostone, sold under the brand name Amitiza among others, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company. The drug was developed by Sucampo Pharmaceuticals and approved by the Food and Drug Administration (FDA) in 2006. It was recommended for use in the UK by the National Institute for Health and Care Excellence (NICE) in July 2014. Health Canada approved the drug in 2015. Lubiprostone received approval from the Food and Drug Administration in 2008, to treat irritable bowel syndrome with constipation (IBS-C), and in 2013, for the treatment of opioid-induced constipation in adults with chronic noncancer pain. It is available as a generic medication.
== Medical uses == Bremelanotide is used for the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Specifically, it is only recommended in those who have the condition without an underlying cause, such as medical, psychiatric, or relationship problems. Researchers have questioned the relevance and validity of the rating scales and outcomes on which bremelanotide was assessed, as well as the drug's effect sizes for these, concluding that benefits may only be modest. It should be used at least 45 minutes before anticipated sexual activity. Only one dose per 24 hours or no more than eight doses per month is recommended. It should be stopped after eight weeks if there is no improvement in sexual desire and associated distress.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.